The combination of subcutaneous daratumumab with VRd was approved in July 2024 for induction and consolidation in patients ...

Subcutaneous immunotherapy injections work the same way as their intravenous counterparts — by changing or enhancing a person’s immune responses to cancer. Immunotherapy for cancer is a broad category ...

PD-1 inhibitors belong to a class of medications known as immune checkpoint inhibitors, which have become an important part of many modern cancer treatment plans. PD-1 inhibitors work by helping the ...

Tecentriq Hybreza, a subcutaneous delivery of the drug, was approved for certain types of sarcoma, in addition to lung, skin and liver cancers. The Food and Drug Administration (FDA) approved ...

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute “This approval is significant for ...

DIPCAN, a multidimensional approach to precision oncology: Harnessing genomic, clinical, pathological and radiographic data to advance personalized cancer treatment. This is an ASCO Meeting Abstract ...

CHICAGO — Administering the bispecific antibody amivantamab (Rybrevant) subcutaneously rather than intravenously in combination with lazertinib (Leclaza) not only reduces administration times but also ...

Subcutaneous administration is preferred by patients, physicians and healthcare providers, and is associated with a reduction in healthcare costs1,2,3 Treatment with Phesgo is over 90% faster, ...